Valerie L. Baker

Valerie L. Baker

Auto-generated profile, based on publicly available information

Valerie L. Baker

Division of Reproductive Endocrinology and Infertility, Department of Gynecology and Obstetrics, Johns Hopkins University School of Medicine , Baltimore, MD

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 April 2025 in Human Reproduction
Verified
Journal Article
Closed access
VBValerie L Baker
Valerie L Baker
SDSilke Dyer
Silke Dyer
GCGeorgina M Chambers
Georgina M Chambers
EKElena Keller
Elena Keller
MBManish Banker
Manish Banker
GAG David Adamson
G David Adamson
STUDY QUESTION: What were the rates of utilization, effectiveness, and safety for assisted reproductive technology (ART) throughout the world in 2017 and 2018, and what trends were observed? SUMMARY ANSWER: The total reported number of ART fresh and frozen cycles conducted in 83 participating countries was 2 913 498 in 2017 and 3 303 505 in 2018, with 5-year trends including an increasing proportion of cycles utilizing frozen embryo transfer (FET) and an increasing number of cycles utilizing pre-implantation genetic testing (PGT). WHAT IS KNOWN ALREADY: Prior reports from the International Committee Monitoring ART (ICMART) have reported on the utilization, effectiveness, and safety of ART from participating countries, with an increase in the number of cycles and number of participating countries over time. These reports have described regional differences in the utilization of ART overall, as well as differences in the utilization of specific practices such as ICSI, PGT and single embryo transfer. Past reports demonstrated that rates of delivery per cycle have increased and rates of multiple gestations have decreased over time. STUDY DESIGN, SIZE, DURATION: This retrospective, cross-sectional survey describes ART procedures performed globally in 2017 and 2018. Data were submitted to ICMART by participating countries from national or regional registries. PARTICIPANTS/MATERIALS, SETTING, METHODS: There were 83 countries which provided data for cycles performed in 2017 or 2018, with the majority of countries providing data for both years. Aggregate data are reported for each participating country and analysed using methods developed by ICMART to calculate measures of utilization, effectiveness, and safety. MAIN RESULTS AND THE ROLE OF CHANCE: A total of 2 913 498 cycles and 671 012 babies born were reported for treatment performed in 2017, increasing to 3 303 505 cycles and 728 383 babies born for treatment performed in 2018. After imputing data for non-reporting centres in reporting countries, the estimated number of cycles performed in 2017 was 3 107 188 resulting in an estimated 814 588 babies. For 2018, the estimated number of cycles was 3 568 635 resulting in an estimated 870 814 babies. Utilization of ICSI for autologous fresh non-PGT cycles declined slightly compared with 2014 (54.6% in 2017 and 57.3% in 2018 compared with 64.8% in 2014). The percentage of transfers which were of frozen embryos was 55.7 % in 2017 and 57.9% in 2018, up from 38.9% in 2014. Among all countries, including those which reported no ‘freeze all’ cycles, the percentage of ‘freeze all’ cycles was 30.5% in 2017 and 32.7% in 2018, up from 13.1% in 2014. In countries reporting at least one retrieval cycle in which all embryos were frozen, the percentage of retrievals with no fresh embryo transfer increased (36.2% in 2017 and 36.8% in 2018, up from 20.1% in 2014). The number of PGT cycles in 2018 (172 247) was nearly 5-fold higher than the number reported in 2014 (36 512) with wide regional variation in utilization of PGT observed. In 2017, the delivery rate for autologous oocytes was 23.5% per oocyte retrieval, with a cumulative delivery rate of 36.4% per retrieval (excluding cycles which utilized PGT). The delivery rates per embryo transfer were 31.8% per autologous fresh transfer, 32.5% per autologous frozen transfer, and 47.3% per transfer after PGT. The delivery rate for transfers utilizing donor oocytes was 33.1% (combined fresh transfer and frozen transfers). In 2018, the delivery rate for autologous oocytes was 23.8% per oocyte retrieval, with a cumulative delivery rate of 37.3% per retrieval (excluding cycles which utilized PGT). The delivery rates per embryo transfer were 31.3% per autologous fresh transfer, 31.9% per autologous frozen transfer, and 48.4% per transfer after PGT. The delivery rate for transfers utilizing donor oocytes was 34.3%. The multiple delivery rate with autologous fresh transfer was 19.7% in 2017, and 18.3% in 2018. For autologous FET, the multiple delivery rate was 16.2% in 2017, and 14.9% in 2018. With oocyte donation (combined fresh and frozen embryo transfers), the multiple delivery rate was 15.9% in 2017, and 13.4% in 2018. Finally, the multiple delivery rate for cycles utilizing PGT was 6.9% in 2017 and 5.5% in 2018. LIMITATIONS, REASONS FOR CAUTION: The data and analysis presented are dependent on the quality and completeness of the data submitted to ICMART, which varies globally. There is little data from the Middle East and some countries in Asia. It is important to note that delivery rates per transfer after PGT required the availability of embryos suitable for transfer, and therefore should not be interpreted as suggesting that PGT increases the overall success of ART per oocyte retrieval. Because of an updated methodology in the calculation of delivery rates and number of babies born, direct comparisons with past reports for these metrics cannot be made. Data are observational and it is not possible to determine the causes for regional differences in utilization, effectiveness, and safety, which are likely due at least in part to regional differences in socioeconomics, culture, resources, and regulations. WIDER IMPLICATIONS OF THE FINDINGS: The ICMART report is the most comprehensive summary of global ART utilization, effectiveness and safety, currently available. There remain regional disparities in the utilization of ART, suggesting differences in access to care. These data can be used by healthcare professionals, healthcare authorities, patients, and the general public to guide research, decision-making, and policy. The reasons behind regional differences in utilization and effectiveness need to be better understood and addressed. STUDY FUNDING/COMPETING INTEREST(S): ICMART received unrestricted grants from Abbott and Ferring Pharmaceuticals. ICMART also received financial support from the following organizations: American Society for...

8 May 2026 in Human Reproduction
Verified
Journal Article
Open access
FZFernando Zegers-Hochschild
Fernando Zegers-Hochschild
SDSilke Dyer
Silke Dyer
GAG David Adamson
G David Adamson
VBValerie Baker
Valerie Baker
KBKurt Barnhart
Kurt Barnhart
CWChristine Wyns
Christine Wyns
STUDY QUESTION: What updates of the International Glossary on Infertility and Fertility Care are required, to reflect contemporary scientific knowledge, social needs, and inclusive definitions, while harmonizing international communication across clinical, research, policy, and public domains? SUMMARY ANSWER: This 4th edition presents 348 consensus-based terms and definitions, including numerous revisions from the previous edition and 79 newly introduced definitions reflecting advances in reproductive science, technology, and evolving social contexts. WHAT IS KNOWN ALREADY: Previous glossary editions (2006, 2009, 2017) established internationally recognized definitions related to clinical practice, research, and policy. The 2017 edition comprised 283 terms and, among many others, expanded the concept of infertility to include not only its recognition as a disease, but also as an impairment of function generating disability. The glossary has been extensively used worldwide and has contributed to international standardization of data collection, appropriate comparison of outcome measures, and provided a reference for all stakeholders including policy makers. STUDY DESIGN, SIZE, DURATION: Under guidance of the organizing committee, 21 professionals from across the world, and representing expertise in different sub-specialties, formed five working groups: clinical definitions; outcome measures; embryology laboratory; clinical and laboratory andrology; and epidemiology, public health and gender related definitions. The definitions from the previous glossary were evaluated and new terms identified. All definitions were then reviewed by an international advisory panel of nine experts that evaluated the glossary from scientific, ethical, cultural, and policy perspectives. PARTICIPANTS/MATERIALS, SETTING, METHODS: Between November 2024 and October 2025, periodical virtual meetings were held within and between working groups and the organizing committee. Following circulation of the first consensually agreed draft, a one-day in-person meeting with representatives of all working groups and members of the international advisory panel was held at ESHRE, June 2025. Most terms and definitions were discussed and agreed. In the absence of agreement, further discussions were held between the organizing committee, working group chairs and members of the advisory panel. It had been determined at the outset that final disagreement would be resolved via a two-third majority vote. All terms and definitions were, however, reached by consensus and adopted following a final round of review and approval by all authors. MAIN RESULTS AND THE ROLE OF CHANCE: The glossary now includes 348 terms. Compared to the previous edition, 14 terms were deleted, numerous terms modified and 79 new terms were added. Modifications reflect current scientific knowledge, technological advancements, and inclusivity related to gender and family structures. Chance does not play a role, as all definitions are consensus-based. LIMITATIONS, REASONS FOR CAUTION: Some terms may require future refinement as scientific knowledge evolves and societal contexts change. The glossary reflects consensus rather than empirical testing of all definitions. WIDER IMPLICATIONS OF THE FINDINGS: This glossary provides a global reference for standardized terminology, supporting clinical care, research, international comparisons, policy making, patient communication, and reproductive health literacy. STUDY FUNDING/COMPETING INTEREST(S): Neither ICMART, responsible for conducting this project, nor any of the participants received specific financial support for their activities in this project. Ferring provided ICMART with a fixed amount to cover venue costs and a one-day hotel accommodation for participants attending the in-person meeting held prior to the ESHRE Congress in June 2025. Disclosures were provided by all authors, and none reported any conflict of interest related to this manuscript. TRIAL REGISTRATION NUMBER: N/A.

17 March 2022 in F&S Reports
Verified
Journal Article
Open access
KBKaren C. Baker
Karen C. Baker
ASAnne Z. Steiner
Anne Z. Steiner
KHKarl R. Hansen
Karl R. Hansen
KBKurt T. Barnhart
Kurt T. Barnhart
MCMarcelle I. Cedars
Marcelle I. Cedars
HZHeping Zhang
Heping Zhang
To determine the reproducibility of the World Health Organization Fifth Edition (WHO5) strict grading methodology by comparing the percentage of morphologically normal sperm (PNS) recorded by the core laboratory with results obtained at the fertility centers participating in a multisite clinical trial. Secondary cohort analysis of data from the Males, Antioxidants, and Infertility trial. Fertility centers. Semen values of 171 men participating in a multicenter, double-blind, randomized, placebo-controlled trial evaluating the effect of antioxidants on male fertility. Not applicable. Strict morphology expressed as PNS as determined at each fertility center and the core central laboratory for the same semen sample. No correlation was found in the PNS values for the same semen sample between the core laboratory and fertility center laboratories either as a group or by individual site. Interobserver agreement was similarly low (κ = 0.05 and 0.15) between the core and fertility laboratories as a group for strict morphology, categorized by the WHO5 lower reference limits of 4% and 0, respectively. Moderate agreement was found between the core and 2 individual fertility laboratories for the cutoff value of 0 (κ = 0.42 and 0.57). The remainder of the comparisons demonstrated poor to fair agreement. Strict morphology grading using the WHO5 methodology demonstrated overall poor reproducibility among a cohort of experienced fertility laboratories. This lack of correlation and agreement in the PNS values calls into question the reproducibility, and thereby the potential applicability, of sperm strict morphology testing.

10 June 2025 in JNCI Cancer Spectrum
Verified
Journal Article
Open access
CAChelsea Anderson
Chelsea Anderson
AWAlexis C Wardell
Alexis C Wardell
ADAllison Deal
Allison Deal
JMJennifer E Mersereau
Jennifer E Mersereau
KCKatie Cameron
Katie Cameron
HNHazel B Nichols
Hazel B Nichols
Background: Evidence of the success of in vitro fertilization (IVF) procedures is critical for informed decision making before and after cancer treatment. We compared IVF outcomes between women with and without cancer. Methods: Using data from a national IVF database—the Society for Assisted Reproductive Clinic Outcomes Reporting System, linked to statewide cancer registries and birth certificates in 9 states—we identified women who initiated IVF after a cancer diagnosis. Fertility preservation was defined as oocyte retrieval ≤90 days after cancer diagnosis, and IVF after cancer treatment as retrieval >90 days postdiagnosis. Number of oocytes retrieved and conception and livebirth rates were compared between these groups and a comparison group of women without cancer in couples with male factor infertility only. Results: Compared with retrievals for male factor infertility only (n = 81 370), the number of oocytes retrieved was not significantly different for women who underwent retrieval for fertility preservation (n = 2941) but was significantly lower for women who underwent retrievals after cancer treatment (n = 2479) (mean difference = −2.99, 95% confidence interval [CI] = −3.40 to 2.59). Rate of conception as a function of transfer attempts and likelihood of livebirth after conception also did not significantly differ for fertility preservation (n = 291) compared with male factor infertility only (n = 34 410). Women with IVF after cancer treatment (n = 672) had a lower rate of conception (hazard ratio = 0.70, 95% CI = 0.61 to 0.79) but a similar overall likelihood of a livebirth after conception, relative to the group with male factor infertility only. Conclusion: IVF outcomes may be maximized when ovarian retrieval is initiated before cancer treatment.

7 March 2024 in medRxiv
Verified
Preprint
Open access
PDF file
SNSusan Nasab
Susan Nasab
EGEthan K Gough
Ethan K Gough
ENElisabeth Nylander
Elisabeth Nylander
MBMostafa A. Borahay
Mostafa A. Borahay
JSJames Hugh Segars
James Hugh Segars
KCKatherine Cameron
Katherine Cameron
Capsule In this study the presence of uterine fibroids was significantly associated with an increased risk of development of hypertensive disorders of pregnancy even when accounting for age and BMI in meta-regression. This finding has potential implications for risk stratification and monitoring for hypertension during pregnancy in this population. Objective To examine the association between uterine fibroids and the development of hypertensive disorders in pregnancy. Data sources Cochrane, Embase, PubMed, MEDLINE, Scopus, and Web of Science databases were searched from inception through April 2023. Study Selection and Synthesis Cohort, case-control, or case series studies including uterine fibroid status and hypertensive disorders of pregnancy status were included. The comparison group was pregnant women without uterine fibroids. Inverse-variance weighted random effects models were used to pool RR and OR estimates separately. Age and BMI were explored as potential sources of heterogeneity using inverse-variance weighted meta-regression. Main Outcomes Hypertensive disorders of pregnancy (HDP) defined as gestational hypertension, pre-eclampsia, eclampsia, superimposed preeclampsia, or hemolysis, elevated liver enzymes, and low platelets (HELLP) syndrome. Results A total of 17 studies were included (Total N=1,374,395 participants, N=64,968 with uterine fibroids). Thirteen studies were retrospective cohorts and four were case-control studies. Women with uterine fibroids had a significantly higher risk of hypertensive disorders in pregnancy compared to women without uterine fibroids with RR 1.74 (95% CI 1.33-2.27, p<0.01), and OR 2.87 (95% CI 1.38-5.97, p<0.01), in cohort studies and case-control studies, respectively. In meta-regression analyses, age did not significantly change the positive association between uterine fibroids and hypertensive disorders in pregnancy. Conclusion Uterine fibroids were associated with an increased risk of hypertensive disorders of pregnancy when all available literature was synthesized, including when shared risk factors are examined in meta-regression analyses. Relevance If confirmed in future studies, investigations into the mechanisms of this association are needed as this finding potentially has implications for risk stratification and monitoring for hypertensive disorders of pregnancy in this population. Trial Registration PROSPERO, ID # 331528

30 April 2025 in JNCI: Journal of the National Cancer Institute
Verified
Journal Article
Closed access
ACAbby L Chen
Abby L Chen
SLShufeng Li
Shufeng Li
VBValerie L Baker
Valerie L Baker
Philip LupoPhilip Lupo
Philip Lupo
HNHazel B Nichols
Hazel B Nichols
BLBarbara Luke
Barbara Luke
Background: Advances in cancer treatment have led to an increased number of survivors who may subsequently have children. We aim to describe the prevalence of a parental cancer history with and without the utilization of in vitro fertilization (IVF) in several states in the United States. Methods: This study used data from IVF cycles resulting in live births reported to the Society for Assisted Reproductive Technology Clinic Outcome Reporting System from 2004 to 2018. These were linked to birth certificates and cancer registries in 3 states (New York, Massachusetts, and North Carolina). For each IVF-conceived delivery, the subsequent 10 deliveries were used as the naturally conceived comparison group. A parent’s cancer history was included if the diagnosis preceded the birth of the first child. Results: There were 814 658 births (82 544 IVF-conceived and 732 114 naturally conceived births) in our analysis. Among births conceived naturally, 0.5% of mothers and 0.4% of fathers had a cancer history compared with 1.2% of mothers and 1.8% of fathers among IVF-conceived births. The prevalence of cancer history increased over the study period (P ≤.004). The most common cancers among mothers were thyroid or endocrine (28.7%) and breast (12.2%) vs male genital (26.3%) and thyroid or endocrine (9.1%) among fathers. There were higher rates of male and female genital malignancies, female breast, and female lymphoid or hematopoietic cancers among parents who conceived with IVF (P < .001). Conclusions: Overall, 1.1% of all births and 3.0% of IVF-conceived births had at least 1 parent with a cancer history with an increasing prevalence over the study period, highlighting the importance of oncofertility programs.